A comparative analysis of prognostic factor models for follicular lymphoma based on a phase III trial of CHOP-rituximab versus CHOP + 131iodine--tositumomab. [electronic resource]
Producer: 20140714Description: 6624-32 p. digitalISSN:- 1557-3265
- Adult
- Aged, 80 and over
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Murine-Derived -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Clinical Trials, Phase III as Topic
- Cyclophosphamide -- administration & dosage
- Disease-Free Survival
- Doxorubicin -- administration & dosage
- Hemoglobins -- metabolism
- Humans
- Kaplan-Meier Estimate
- Lymph Nodes -- pathology
- Lymphoma, Follicular -- blood
- Middle Aged
- Multivariate Analysis
- Organ Size
- Prednisone -- administration & dosage
- Prognosis
- Proportional Hazards Models
- Rituximab
- Vincristine -- administration & dosage
- Young Adult
- beta 2-Microglobulin -- blood
No physical items for this record
Publication Type: Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.